Lynx Completes $4M Private Stock Placement | GenomeWeb

NEW YORK, Jan. 2 (GenomeWeb News) - Lynx Therapeutics today said it has completed a $4 million private financing of common stock and warrants for common stock.

The financing included the sale of 800,000 newly issued shares of common stock at $5.00 per share and the issuance of warrants to purchase 200,000 shares of common stock at an exercise price of $6.25 per share.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.